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Introduction: Understanding protective human immunity against mycobacteria is
critical to developing and evaluating new vaccines against tuberculosis. Children are
the most susceptible population to infection, disease, and death from tuberculosis, but
also have the strongest evidence of BCG-inducible protection. Limited amounts of blood
can be obtained for research purposes in paediatrics and therefore there is a need for
high-yield, low-volume, human immunology assays.
Methods: We transformed BCG Danish with plasmids encoding luciferase full operon
derived from Photorhabdus luminescens together with Green Fluorescent Protein
and antibiotic selection markers. We characterised the luminescent and fluorescent
properties of this recombinant BCG strain (BCG-GFP-LuxFO) using a luminometer and
flow cytometry and developed a paediatric whole blood in vitro infection model.
Results: Luminescence of BCG-GFP-LuxFO correlated with optical density (Spearman
Rank Correlation coefficient r = 0.985, p < 0.0001) and colony forming units (CFUs)
in liquid culture medium (r = 0.971, p < 0.0001). Fluorescence of BCG-GFP-LuxFO in
paediatric whole blood was confirmed by flow cytometry in granulocytes and monocytes
1 h following infection. Luminescence of BCG-GFP-LuxFO in whole blood corresponded
with CFUs (r = 0.7123, p < 0.0001).
Conclusion: The BCG-GFP-LuxFO assay requires 225 µL whole blood per sample,
from which serial luminescence measurements can be obtained, together with
biochemical analysis of supernatants and cellular assay applications using its fluorescent
properties. This offers the opportunity to study human-mycobacterial interactions using
multiple experimental modalities with only minimal blood volumes. It is therefore a
valuable method for investigating paediatric immunity to tuberculosis.
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INTRODUCTION
An understanding of protective immunity to tuberculosis
is required to inform vaccine design, contribute to the
World Health Organization’s Roadmap to end TB in children
and adolescents, and achieve the goal of zero childhood
tuberculosis deaths (1–6). The study of human immunity
to mycobacteria is key to a better understanding of the
disease, given the inherent constraints on how much can
be extrapolated from animal models (7–10). Understanding
paediatric immune responses is of particular importance as
young children are the most susceptible to developing infection,
disease, or dying following exposure, but also the group
for whom there is the strongest evidence of BCG-inducible
protection against tuberculosis (11–15). However, phlebotomy
is technically challenging in children, can be distressing for
the child and family, and research blood sample volumes
are small (16). As a consequence, the number of studies
conducted in children remains very limited, and a critical need
to refine laboratory methodology remains. New methods need
to maximise the scientific yield from small volumes of blood
from children affected by M. tuberculosis who participate in
research studies.
One widely published method to measure human
mycobacterial immunity is the lux assay (17–27). The
BCG-lux assay involves a 96 h incubation of whole blood
in culture medium with BCG-lux, a strain of BCG constitutively
expressing luxAB genes, which encode a luciferase enzyme
from Vibrio harveyii on a plasmid together with a gene
encoding hygromycin resistance to enable selection and
prevent loss of the plasmid (17–27). Luminescence of samples
is measured using a luminometer at baseline and 96 hours
following centrifugation and red cell lysis of the pellets,
dilution and addition of the luciferase substrate. The assay also
provides the opportunity to store supernatants for subsequent
analysis. A growth ratio is derived by the luminescence
measured at 96 h divided by that measured at baseline.
Another mycobacterial growth assay, the Mycobacterial Growth
Inhibition Assay, measures the Time to Detection in an
automated mycobacterial culture system (MGIT) of a lysed
sample of whole blood or peripheral blood mononuclear cells
that has been co-cultured with an inoculum of mycobacteria for
96 h (28–34).
We aimed to develop an improved luxwhole blood assay using
an auto-luminescent recombinant BCG strain expressing the
luciferase full operon derived from Photorhabdus luminescens,
which includes the genes encoding the bacterial luciferase
enzyme and the genes for the synthesis of the substrate
for the luminescence reaction (35–37). This would enable
quantification of luminescence in a continuous manner from
the same sample, and thereby decrease the blood volumes
required to evaluate mycobacterial growth. Co-expression of a
green fluorescent protein would enable cellular assays on cell
pellets in addition to biochemical evaluation of supernatants,
further enhancing the scientific yield from a given volume
of blood.
MATERIALS AND METHODS
Mycobacterial Culture Methods
BCG is a hazard group 2 organism and therefore all experimental
work was conducted in category Level 2 laboratories. Liquid
mediumwas prepared with 4.7 g of 7H9Middlebrook dried broth
(Fluka/Sigma-Aldrich, Gillingham, UK), 2.5ml of 20% Tween 80
(Acros Organics/Thermo Fisher Scientific, Waltham, MA, USA),
4ml of 50% glycerol (VWR, Radnor, PA, USA), and dissolved
in 893.5ml of dH2O. This was then autoclaved for 15min at
100 kPa at 1210◦C. Once cooled 100ml of Albumin Dextrose
Catalase (ADC) supplement (BD, Franklin Lakes, NJ, USA) was
added and selection antibiotics at the specified concentrations
(Hygromycin, Sigma-Aldrich, Gillingham, UK; Kanamycin,
Glyco/Life Technologies, Carlsbad, CA, USA). Forty microlitre
of 20% Tween 80 was added for each 15ml of medium. Solid
medium was prepared with 21 g of 7H11 agar (Fluka/Sigma-
Aldrich, Gillingham, UK) and 10ml 50% glycerol made up to a
final volume of 900ml with dH2O in a 1 L bottle and autoclaved
for 15min at 100 kPa at 1210◦C. Once cooled, 100ml of
Oleic acid Albumin Dextrose Catalase (OADC) supplement (BD,
Franklin Lakes, NJ, USA) was added and selection antibiotics
at the specified concentrations. Colony Forming Units (CFU)
were counted using serial dilutions in sterile Phosphate Buffered
Saline of 10 µL of the experimental sample plated onto solid
culture medium after 21 days. Liquid and solid cultures were
incubated at 37◦C. Optical density (OD600) of 0.5ml volumes of
bacteria in liquid culture was measured using a Biophotometer
Plus spectrophotometer (Eppendorf, Hamburg, Germany).
Transformation of BCG
The parent strain was BCG Danish (Staten Serum Institute,
Copenhagen, Denmark). The following plasmids were used:
pMV306DIhsp+LuxG13: Kanamycin resistance integrase-
free integrative reporter plasmid harbouring the Luciferase
Full Operon (Photorhabdus luminescens) (35, 37, 38).
(pMV306DIhsp+LuxG13, Addgene plasmid # 49999) (37);
pBS-Int: a suicide plasmid that expresses the integrase gene
necessary for the integration of pMV306DIhsp+LuxG13 into the
chromosome after electroporation. (Addgene plasmid # 50000);
pGFPHYG2: A hygromycin resistance replicative plasmid that
expresses gfpmut3, encoding Green Fluorescent Protein, and
(39) (pGFPHYG2, Addgene plasmid # 30173).
Transformations were carried out as per the protocol of
Goude and Parish (40) Briefly, 50mL of culture in logarithmic
growth phase were centrifuged at 3000 × g for 10min at room
temperature. The cells were washed twice with 50ml and then
20ml pre-warmed 10% glycerol plus 0.05% Tween 80. The
cells were resuspended in 500 µL of 10% glycerol and 200
µL was transferred into electroporation cuvettes. One hundred
nanograms DNA of each plasmid was used. Electroporation was
carried out with a single pulse of 2.5 kV, 25 µF with the pulse-
controller resistance set at 1,000 resistance. The suspension
was then immediately transferred into 10mL 7H9 media and
incubated without antibiotics for 16 h. Bacteria were harvested by
centrifugation at 3000 × g for 10min and dilutions were plated
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TABLE 1 | Demographic characteristics of 9 participants.
Median age in years (interquartile range) 7.3 (6.5–8.5)
Male:Female ratio 1:2
TST result>10mm 3
out on 7H11 plates with kanamycin at 20µg/mL and hygromycin
at 50µg/mL. Plates were incubated at 37◦C until discrete colonies
appeared. Colonies were picked and incubated in 7H9 liquid
media at 37◦C. Stocks were frozen down in 15% glycerol. The
resultant strain is named BCG-GFP-LuxFO.
Quantification of Luminescence and
Detection of Fluorescence of Bacteria
Luminescence of BCG-GFP-LuxFO was quantified in Relative
Light Units/second (RLU/s) using the Sirius Tube Luminometer
(Berthold Detection Systems GmbH, Pforzheim, Germany)
immediately following removal from the incubator.
Direct fluorescence of bacteria was measured in a 1:1 mixture
of non-fluorescent BCG and BCG-GFP-LuxFO fixed in 2%
paraformaldehyde using a LSRII Fortessa flow cytometer (BD,
San Jose, CA, USA).
Paediatric Whole Blood BCG-GFP-LuxFO
Assays
Whole blood was collected in lithium-heparin vacutainer tubes
(BD, Wokingham, UK) from children aged 5–15 years old
participating in a household contact tuberculosis study in The
Gambia (41–44). Each independent experiment consisted of
participants who were selected based upon having had household
exposure to the same adult with smear-positive pulmonary
tuberculosis, no symptoms of tuberculosis, and included children
with positive and negative tuberculin skin test responses as part
of a larger study exploring factors influencing latent tuberculosis
infection in children. Approvals were obtained from The MRC
Unit The Gambia Scientific Coordinating Committee and The
Gambia Government/MRC Joint Ethics Committee (SCC1405).
Experiments were carried out in 2015 at MRC Unit The Gambia
at the London School of Hygiene and Tropical Medicine.
Participant characteristics are shown in Table 1.
A vial of BCG-GFP-LuxFO stored in 15% glycerol at −70◦C
was thawed and added to 15ml 7H9 Middlebrook broth
supplemented with ADC and kanamycin (final concentration
20µg/ml) and hygromycin (final concentration 50µg/ml) +40
µl 20% Tween 80 in a 250ml Erlenmeyer flask (Corning B.V Life
Sciences, Amsterdam, The Netherlands). This was incubated in
an orbital shaking incubator at 37◦C with daily measurements
of 0.5ml samples for luminescence and optical density. Further
liquid medium was added as required to maintain the bacteria in
logarithmic growth phase until the day of the assay. Immediately
prior to the blood samples being taken, an aliquot of the stock
in logarithmic phase was diluted down to 3.3 x 105 RLU/ml/s
BCG-GFP-LuxFO. This concentration of BCG-GFP-LuxFO gave
baseline luminescence readings of whole blood samples 10-fold
higher than the experimentally determined detection threshold
of the luminometer used for this assay to enable a dynamic range.
A schematic of the paediatric whole blood assay is shown
in Figure 1. Whole blood was mixed in a ratio of 1:1 with
RPMI 1640 culture medium (Sigma-Aldrich, Gillingham, UK)
containing 2.5% 1M HEPES buffer and 1% L-glutamine (both
Sigma-Aldrich). The BCG-GFP-LuxFO in 7H9–0.05% Tween 80-
ADC with kanamycin at 20µg/mL and hygromycin at 50µg/mL
was added at a ratio of 1 part BCG-GFP-LuxFO: 9 parts whole
blood in culture medium. For the medium only control samples,
bacterial medium alone was added in the same ratio of 1:9.
Four 0.5ml aliquots of each experimental condition were placed
into sterile lidded 75 × 12mm standard tubes (Corning B.V
Life Sciences, Amsterdam, The Netherlands). This equates to a
total volume of 900 µL whole blood for each condition with
triplicate tubes for quantifying luminescence and a fourth tube to
enable determination of CFU during this method development.
Triplicate growth controls of the recently diluted BCG-GFP-
LuxFO in 1:9 ratio with further liquid medium were prepared
in parallel to confirm that the bacteria remained in logarithmic
growth phase at the time of inoculation.
Detection of Fluorescence in Paediatric
Whole Blood
One hour after BCG-GFP-LuxFO or medium alone were added,
samples were centrifuged at 2,000 g for 10min. The cell pellet was
resuspended in RPMIwith 2mMEDTA to remove adherent cells,
and red cells were then lysed with a 10min incubation with red
cell lysis buffer (eBioscience, Thermo Fisher Scientific, Waltham,
MA, USA), washed, a further 10min incubation with red cell lysis
buffer and then washed twice. 0.4 µL Live/Dead Aqua (Thermo
Fisher Scientific, Waltham, MA, USA) was added and incubated
for 20min in the dark at room temperature. Cells were then
washed and fixed in FACS Lysing solution for 10min (BD, San
Jose, CA, USA), washed twice and resuspended in PBS with 2%
Fetal Calf Serum and 0.5mM EDTA. Data were acquired with a
LSRII Flow Cytometer (BD, San Jose, CA, USA). Cells were first
gated based on their light scatter properties and cellular debris
were excluded. Only singlets and live cells were then included in
the analysis. Compensation was calculated for each fluorescence
using single colour stained whole blood samples (i.e., medium
only control sample stained with Live/Dead dye and unstained
BCG-GFP-LuxFO infected sample). Data analysis was performed
using FlowJo v10.5.3 for Mac (Treestar Inc., USA).
Detection of Luminescence in Paediatric
Whole Blood
Luminescence of each whole blood aliquot was measured using
the Sirius Tube Luminometer (Berthold Detection Systems
GmbH, Pforzheim, Germany) immediately following removal
of the tubes from the incubator. Luminescence was measured
1 h after the bacteria were added to ensure that the sample
had equilibrated to 37◦C in the incubator, and at 24, 48, 72,
and 96 h. Three luminescence measurements at each time point
were recorded, and the mean of these three measurements was
recorded. At each time point, mean background luminescence
from three medium-only control samples was also measured
and then subtracted. Ten microlitre aliquots were removed
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from a fourth tube every 24 h and dilutions were plated for
determination of CFUs and correlation to the luminescence
measurements in the same tube.
Statistical Methods
Spearman’s Rank Correlation coefficients and coefficients
of variation were calculated using Prism 7 for MacOS
FIGURE 1 | Schematic of BCG-GFP-LuxFO whole blood assay method.
FIGURE 2 | (A) Luminescence and optical density growth curves of BCG-GFP-LuxFO in liquid culture. Luminescence is shown on the left y axis, indicated in red, and
optical density on the right y axis, indicated in blue. Arrowheads denote addition of media to maintain bacteria in logarithmic growth phase. (B) Correlation between
optical density and luminescence measurements of BCG-GFP-LuxFO in 7H9 liquid medium. n = 16 pairs of observations. Spearman rank correlation coefficient, r =
0.9853 (95% CI:0.9556:0.9952; p < 0.0001). RLU, Relative Light Units.
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FIGURE 3 | Correlation between colony forming units and luminescence of
BCG-GFP-LuxFO in liquid 7H9 medium. n = 15 pairs of observations.
Spearman rank correlation coefficient r = 0.9714 (95% CI: 0.9112–0.9910; p
< 0.0001).
FIGURE 4 | Flow cytometric confirmation of fluorescence of BCG-GFP-LuxFO
in a 1:1 mixture of non-fluorescent BCG and BCG-GFP-LuxFO.
X (Graphpad Software, La Jolla, CA, USA). Two-tailed
significance testing was applied with p < 0.05 considered to be
statistically significant.
RESULTS
Characteristics of BCG-GFP-LuxFO in
Liquid Culture
BCG-GFP-LuxFO demonstrated logarithmic growth in liquid
culture medium (Figure 2A) with luminescence and optical
density correlating with Spearman Rank Correlation coefficient
of 0.985 (95% confidence interval 0.956–0995, p < 0.0001)
(Figure 2B). Colony forming units and luminescence of
BCG-GFP-LuxFO in liquid culture medium correlated
with Spearman rank correlation coefficient r = 0.9714
(95% CI: 0.9112–0.9910; p < 0.0001) (Figure 3). The RLU:
CFU ratio for BCG-GFP-LuxFO was 0.05 RLU: 1 CFU.
Fluorescence of BGC-GFP-LuxFO was confirmed by flow
cytometry (Figure 4).
Fluorescence in Paediatric Whole Blood
Assay
Following centrifugation to obtain the cell pellet, 350–400 µL of
supernatant could be stored from each 0.5ml aliquot. One hour
after infection with BCG-GFP-LuxFO, 15% of all cells were GFP
positive, with 26% of granulocytes, 21% of monocytes, and 0.1%
of lymphocytes demonstrating fluorescence based on cell size and
granularity (Figure 5).
Luminescence in Paediatric Whole Blood
Assay
Data were analysed from nine children in three independent
experiments and five timepoints. Luminescence and CFUs
correlated with Spearman rank correlation coefficient r =
0.7123 (95%CI: 0.5230–0.8346; p < 0.0001) (Figure 6). Mean
coefficients of variation in luminescence data across these
experiments were 7.65% for (a) the three measurements
of each tube and 11.5% for (b) the three replicates for
each child.
DISCUSSION
We have developed and evaluated an auto-luminescent
fluorescent BCG reporter strain that demonstrates robust
correlations between luminescence, optical density, and CFUs in
liquid culture. In a high TB-endemicity setting with paediatric
whole blood samples, we were able to demonstrate across three
independent experiments, nine paediatric subjects, and five
timepoints that luminescence and CFU correlated significantly.
The BCG-GFP-LuxFO assay enables serial non-destructive
luminescence measurements over 96 h where each tube contains
225 µL whole blood. Existing assays require 450 µL to generate
a single 96 h growth ratio value in the lux assay or 300 µL
of whole blood to generate the Time to Detection in the
Mycobacterial Growth Inhibition Assay (23, 32, 34). The ability
to quantify luminescence in a non-destructive manner combined
with the fluorescent nature of BCG-GFP-LuxFO means that
following measurement, samples can be centrifuged to carry out
biochemical analyses on the supernatants and cellular analyses
on the cell pellet as required.
BCG-GFP-LuxFO has a relatively low RLU:CFU of 0.05 RLU:
1 CFU, which likely reflects the associated metabolic costs of
constitutive expression of the whole luciferase operon (35–
37). This low RLU:CFU ratio means that the multiplicity of
infection is higher thanwith the lux assay. However, asmeasuring
luminescence in the original lux assay involves lysis of red blood
cells, vortexing with glass beads, and dilution steps, there is
considerable decrease in experimental time with the BCG-GFP-
LuxFO assay compared to the lux assay, and the potential for
automated luminescence measurement (20).
The BCG-GFP-LuxFO assay contributes to the range of
immunological methods available to study human whole blood
responses to mycobacteria. Studies of human whole blood have
made many important contributions to understanding human
mycobacterial immunity and originally led to the identification
of mendelian susceptibility genes and pathways (17, 18, 27,
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FIGURE 5 | Flow cytometric detection of fluorescence of BCG-GFP-LuxFO in whole blood assay. (A) Within the live cell population, GFP– and GFP+ cells were
determined, respectively. (B) Within the live cell population, cells were then gated on either granulocytes (in red), monocytes (in green), or lymphocytes (in blue),
distinguishable by their size and granularity using forward scatter (FSC)/side scatter (SSC) gate. The gate GFP–/GFP+ populations were set based on the medium
only negative control so that the frequency of GFP+ cells = 0% for each cell population. For each plot, the GFP- population is reported in the top left, and the GFP+
population in the top right. Representative data shown from samples from two children one hour after BCG-GFP-LuxFO was added.
FIGURE 6 | Correlation between luminescence and colony forming units in
BCG-GFP-LuxFO paediatric whole blood assay. n = 45 pairs of observations
(samples from three experiments, from 9 children at 5 time points). Spearman
rank correlation coefficient r = 0.7123 (95%CI: 0.5230–0.8346; p < 0.0001).
45, 46). Studying whole blood in paediatric populations with
tuberculosis has highlighted distinct gene expression signatures
with diagnostic potential (47). In light of recent advances in the
immunological definition of the TB spectrum, the BCG-GFP-
LuxFO assay has potential to compliment other researchmethods
in characterising the human host response (8, 46, 48–50).
Whole blood is critical to study the role of neutrophils
in tuberculosis: they are known to be the most common cell
type infected in whole blood samples taken from adult donors
(51); enhance macrophage responses (52); and drive a type I
interferon-inducible transcript signature in adults (45). The small
volume requirements for the BCG-GFP-LuxFO assay combined
with the high data yield means that it is well-suited to research in
paediatric populations affected by tuberculosis.
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